<DOC>
	<DOCNO>NCT02755272</DOCNO>
	<brief_summary>The main purpose study see Pembrolizumab combination chemotherapy ( carboplatin gemcitabine ) safe effective treating patient metastatic triple negative breast cancer . Pembrolizumab drug may help immune system target destroy cancer cell . Pembrolizumab approve FDA treatment advance melanoma metastatic non-small cell lung cancer . However , approve treatment breast cancer .</brief_summary>
	<brief_title>A Study Pembrolizumab With Carboplatin Gemcitabine Patients With Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Women diagnose pathologically confirm metastatic triple negative invasive breast cancer ( centrally confirm immunophenotype negative three receptor ER , PR HER2 ) . Have either evaluable disease , measurable clinical disease : Measurable disease , define least 1 unidimensionally measurable lesion CT scan define RECIST ( version v1.1 ) . Patients receive 2 prior regimen disease metastatic setting . Patients candidate chemotherapy carboplatin gemcitabine . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Patients must willing able provide write informed consent trial Demonstrate adequate organ function define , screen lab perform within 10 day treatment initiation . Absolute neutrophil count ( ANC ) Greater equal 1,500 /mcL . Platelets great equal 100,000 / mcL . Hemoglobin great equal 9 g/dL ≥ 5.6 mmol/L . Serum creatinine OR Measured calculate creatinine clearance ( GFR also use place creatinine CrCl ) less equal 1.5 X upper limit normal ( ULN ) OR great equal 60 mL/min subject creatinine level great 1.5 X institutional ULN . Serum total bilirubin le 1.5 X ULN OR Direct bilirubin less ULN subject total bilirubin level great 1.5 ULN . Aspartate aminotransferase ( AST ) ( SGOT ) Alanine aminotransferase ( ALT ) ( SGPT ) less equal 2.5 X ULN OR less equal 5 X ULN subject liver metastasis . International Normalized Ratio ( INR ) Prothrombin Time ( PT ) less equal 1.5 X ULN unless subject receive anticoagulant therapy . Activated Partial Thromboplastin Time ( aPTT ) less equal 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant . Patients childbearing potential must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Patients participate another trial investigational agent within 4 week first dose study . Patients receive prior therapy use carboplatin/gemcitabine le 12 month begin enrollment subject whose tumor progress treatment carboplatin cisplatin . Patients baseline grade 2 neuropathy . Diagnosis immunosuppression receive steroid therapy immunosuppressive therapy within 4 week study . Active autoimmune disease document history autoimmune disease , syndrome require systemic treatment past 2 year Has evidence interstitial lung disease active , noninfectious pneumonitis Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Known additional malignancy progress and/or require treatment last 5 year . Except basal squamous cell carcinoma skin situ cervical carcinoma complete potentially curative therapy . Life expectancy le 3 month . Prior therapy antiprogrammed cell death 1 ( PD1 ) , antiprogrammed cell death 1 ligand ( PDL1 ) , antiPDL2 , antiCD137 antibody , anticytotoxic Tlymphocyte associate antigen4 ( CTLA4 ) antibody . Pregnant , breastfeeding , expect conceive child within project time trial , start prescreening screen visit 120 day last dose trial treatment . Active infection require systemic therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Triple Negative Breast Cancer</keyword>
</DOC>